THE TAPE
IRTC · Medical Instruments · $3.0B

iRhythm Holdings, Inc. Common Stock

$90.83▼ −1.18%
Last close
Relative strength
9RS
of 99, against every stock▼ -9 on the month
Falling back
Strong industry, weak stock
−37.6%
six months against Medical Instruments
52-week range
−52.8%
from the high
$82.85$192.47
Setup
On no screen
No base, flag or squeeze in place tonight. What is and is not there
No report date on the calendar.
Growth FLATProof PENDING
Quarter to Sep 30, revenue +15% on a year ago
Why it is on no screen

IRTC is off the screens on 2 checks.

A base has formedNo pause of 3 weeks or more inside the last 24 weeks.
Long enough to countNeeds a base first.
Shallow enoughNeeds a base first.
Close to its pivotNeeds a base first.
Relative strengthRS 9 against 70 needed.

Measured against the base-and-breakout thresholds. The other screens use their own numbers, so a name can miss here and still be a fair-looking chart.

Draw
9-dayabout two weeks21-dayabout a month50-dayabout a quarter200-dayabout a year
Support and resistance
Support below
None within the last 120 sessions
Resistance above
$102.62
+13.0% · tested 5× · last 23 sessions ago

Prices this stock has turned at three or more times in the last 120 sessions, with how many times. Where buyers and sellers showed up before, not a forecast, an entry or a stop.

The read

iRhythm Holdings, Inc. Common Stock is not on any of the screens right now. Its relative strength rating is 9, and it sits in Medical Instruments.

Against its industry
Strong industry, weak stockBehind its industry over one and six months while the industry is fully aligned and ahead of the S&P 500.
One month against its industry
-19.7%
Three months against its industry
-21.3%
Six months against its industry
-37.6%

Read against an equal-weighted index of Medical Instruments, which is +31.0% against the S&P 500 over six months Fully aligned.

Peers
Same theme
No themes — common and fine.
Catalyst roadmap

Nothing dated in the next three months that we can ingest automatically.

How it moves on earnings

On average 10.6% either way across its last 8 reports.

Checking your subscription…

Close before the report day to close after it, so it holds whether the company reported before the open or after the close.

The business
Revenue
$854.0M
+14.9% year on year
Operating margin
-5.7%
gross 72.3%
Net margin
-4.6%
Free cash flow
$7.4M
0.2% of market cap
Price to sales
3.51×
Price to earnings
—
not meaningful on a loss

Twelve months to Sep 30, 2026, the four latest quarters in the company’s SEC filings, with the fiscal fourth quarter worked out from the annual report. Revenue growth is the latest quarter against the same quarter a year earlier.

The latest quarter, read by fixed rules · reported Nov 5
Key takeaway
Margins are improving, but the financial turnaround is not yet proven.
Revenue
$221.6M
-1.2% QoQ · +14.9% YoY
Gross margin
74.2%
+1.4 pts QoQ
Net income
−$29.9M
Loss
Free cash flow
−$11.5M
Burning · 34q runway

What the numbers say

  • Revenue +14.9% year over year, -1.2% on the quarter
  • Good: Gross margin 74.2%, +1.4 points on the quarter
  • Weak: Net loss $30M, wider than $381K last quarter
  • Weak: Burning cash: operating cash flow $4M, free cash flow -$12M, worse than $38M last quarter · 34 quarters of cash at this burn
  • Weak: Growth externally funded: capex $16M against operating cash flow $4M
  • Good: Net cash $395M · cash $395M
Revenue by quarter
Free cash flow
Net income
shares +2.9% in a year · net cash $394.7M

What is not obvious

  • Weak: Stock compensation $19M added back, 439% of operating cash flow; -$15M after it
  • Weak: Interest $3M a quarter against an operating loss: the debt is carried by the balance sheet, not operations

The desk’s own read

Flagged as drifting down since the report

Final read
Growth: FLAT · Economic proof: PENDING
Key question: Can the recovery in margins reach operating profit and cash?
The next test is operating profit: net loss $30M, wider than $381K last quarter.

From the company’s 10-Q and 10-K filings, by Market Desk’s rules. Every line, the takeaway and the final read are fixed rules on the filed numbers; nothing reads the press release, and none of it enters a screen or a rating. Every recent reporter.

Tracked funds

Held by 1 of 46 tracked funds at the end of Q3 2026.

Last quarter: 1 added.

Checking your subscription…

From 13F filings, which show long stock only and arrive up to 45 days after the quarter. The broad quant funds are left out.

Flagged by the market sweep
A director or officer changedFiling · 2026-11-14
5.02
No measurable effect: stocks behave like random ones over the next three sessions (1,288 cases over 54 nights).
Closed below its 20- and 50-day on heavy volumeTape · 2026-11-13
below 20d & 50d on 1.8x volume at 93.56
No measurable effect: stocks behave like random ones over the next three sessions (1,780 cases over 60 nights).
GappedTape · 2026-11-13
+5.5%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
New 52-week lowTape · 2026-11-10
2.1x vol
Mixed: stocks have outrun random stocks by 0.6% over three sessions, not consistently enough to call (746 cases over 51 nights). Against their own sector they have outrun by 0.2%.
New 52-week lowTape · 2026-11-07
10.8x vol
Mixed: stocks have outrun random stocks by 0.6% over three sessions, not consistently enough to call (746 cases over 51 nights). Against their own sector they have outrun by 0.2%.
Closed below its 20- and 50-day on heavy volumeTape · 2026-11-07
below 20d & 50d on 10.8x volume at 90.22
No measurable effect: stocks behave like random ones over the next three sessions (1,780 cases over 60 nights).
GappedTape · 2026-11-07
-30.7%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
Moved 5%+ down on earningsTape · 2026-11-07
-30.7% on earnings 2026-11-05
No measurable effect: stocks behave like random ones over the next three sessions (665 cases over 44 nights).

From a separate overnight market sweep, not from the screens on this site. What it flagged, not what it means. The track record is the sweep's own, measured against random stocks over the last 90 days.

In the news
Insiders

No Form 4 filings read for this company in the last six months. That can mean nobody filed, or that this name has not been on a screen long enough for us to have fetched them.

What analysts expect
Strong buy3
Buy12
Hold1
Sell0
Strong sell0

These are analysts’ estimates, not ours, and not a projection this site endorses. They are published here because what the sell side expects is itself a fact about the market.

Checking your subscription…

Gamma concentration

No option open interest for this company. Most listed names have no options at all, and we only read chains for names carrying a dated event, so this is a normal reading rather than a fault.

X-ray

No completed base to compare this one with yet.

A screening and market-analytics tool. Not investment advice. We are not a registered investment adviser. A stock on a screen matches a shape; that is not a prediction. Prices are end-of-day, not live.

What that means, in full
iRhythm Holdings, Inc. Common Stock (IRTC) — The Tape